The Food and Drug Administration's independent panel of advisors on Wednesday recommended GlaxoSmithKline's RSV vaccine for adults ages 60 and older, though they flagged potential safety issues over nervous system disorders that may be tied to the shot. Ten of the FDA advisors said the safety data on GSK's vaccine was adequate, while two said